摘要
目的 研究癌 睾丸抗原 (CT)抗原在经术前化疗的非小细胞肺癌 (NSCLC)中的表达谱 ,以确定NSCLC经化疗、手术后可能的辅助免疫治疗疫苗治疗组成成分。方法 用逆转录 聚合酶链反应 (RT PCR)检测了 5 1例经化疗后手术的原发性NSCLC病人肿瘤组织中 11种CT抗原基因的表达情况。结果 所检测的 11种CT基因在经化疗后的NSCLC表达最高的为MAGE 3,38% ,其次分别为NY ESO 12 1% ,CT10 17% ,LAGE 115 % ,MAGE 4 13% ,SCP 1、SSX1、SSX4均为 12 % ,MAGE 110 % ,SSX2 6 % ,CT72 %。在这些病人中 ,有 34例 (6 7% )病人表达至少 1种CT基因。在不表达所检测的任何CT基因的 17例病人中 ,13例 (76 % )为Ⅰ期病人。MAGE 3和CT10在NSCLC中表现出了随疾病进展而增加的现象 ;反之 ,SCP 1的表达主要在Ⅰ期和Ⅱ期。将NSCLC经病理分类分为鳞癌和腺癌 ,发现鳞癌中至少表达 1种CT基因 (75 % )和共表达CT基因的频率 (5 5 % )均比腺癌 (5 3%和 2 4 % )高。结论 (1)包括MAGE 3、NY ESO 1、LAGE 1等抗原成分的CT抗原疫苗可应用于术前化疗的NSCLC病人的治疗 ;(2 )对不同NSCLC肿瘤分期的病人可采取不同CT抗原成分疫苗 ;(3)对晚期手术和化疗疗效不好的病人和鳞癌病人 ,CT抗原疫苗治疗是一个值得研究的重要方向。
Objective To investigate the possibility of utilizing cancer-testi(CT) antigens as targets for immunotherapy of non-small cell lung cancer(NSCLC) with vaccines. Methods Tissues from 51 NSCLC patients who had chemotherapy prior surgery were assayed for the expression of 11 different CT antigens by RT-PCR. Results Of the 11 CT antigens analyzed, MAGE-3 was found to be expressed most frequently in NSCLC tissues and CT7 the least frequently. The frequencies of CT antigen expression was: MAGE-3 (38%), NY-ESO-1 (21%), CT10 (17%), LAGE-1 (15%), MAGE-4 (13%), SCP-1, SSX1 and SSX4 (12%), MAGE-1 (10%), SSX2 (6%), and CT7 (2%). Among these cases, 34 (67%) expressed at least one CT antigen gene. 13 of the 17 cases in which no CT antigen expression was found in the tumor tissue, the tumors were classified as at the stage I. MAGE-3 and CT10 were found to be expressed more frequently in tissues from patients with late stage diseases while SCP-1 was found more frequently in earlier stages of NSCLC. CT expression was more frequently found in squamous cell carcinoma than in adenocarcinoma. Conclusions (1) Cancer vaccines with CT antigens including MAGE-3, NY-ESO-1, LAGE-1, etc, are suitable for immunotherapy of NSCLC after chemotherapy and surgery. (2) NSCLC patients at different stages of disease may be treated with vaccines of different CT antigen composition. (3) CT antigen vaccines are most attractive for patients with late stage NSCLC and/or squamous cell carcinoma of NSCLC.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2004年第6期464-468,共5页
National Medical Journal of China
基金
美国癌症研究所资助项目 (DesignedGrant)
北京市科技新星资助项目 (H0 2 0 83 2 13 70 13 0 )
北京大学"2 11"工程免疫学科资助项目
北京肿瘤医院科研基金资助项目